Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers

NCT ID: NCT01176851

Last Updated: 2021-10-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-07-31
• Study Completion Date: 2010-10-31

Brief Summary

The purpose of this study is to investigate the pharmacokinetics, the absolute bioavailability and the lung bioavailability of inhaled Glyco pMDI.

Conditions

Healthy

Keywords

None (study in healthy volunteers)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Glyco pMDI

Glyco pMDI 100 µg

Group Type: EXPERIMENTAL

Glycopyrrolate

Intervention Type: DRUG

Single administration of Glyco pMDI 100 µg

Glyco pMDI Charcoal

Glyco pMDI 100 µg + charcoal block

Group Type: EXPERIMENTAL

Glycopyrrolate

Intervention Type: DRUG

Single administration of Glyco pMDI 100 µg after charcoal ingestion

Glyco IV injection

Glyco solution for injection 100 µg

Group Type: ACTIVE_COMPARATOR

Glycopyrrolate

Intervention Type: DRUG

Single intravenous injection of glycopyrrolate 100 µg

Interventions

Glycopyrrolate

Single administration of Glyco pMDI 100 µg

Intervention Type: DRUG

Glycopyrrolate

Single administration of Glyco pMDI 100 µg after charcoal ingestion

Intervention Type: DRUG

Glycopyrrolate

Single intravenous injection of glycopyrrolate 100 µg

Intervention Type: DRUG

Other Intervention Names

CHF 5259; CHF 5259; Robinul Injection

Eligibility Criteria

Inclusion Criteria

1. Males and females healthy volunteers aged 18-65 years;

2. Written informed consent obtained before the first trial related activity.

3. Able to understand the study procedures, the risks involved and ability to be trained to use the devices correctly.

4. Body Mass Index (BMI) between 18.0 and 32.0 kg/m2;

5. Non- or ex-smokers who smoked < 5 pack years;

6. Good physical and mental status;

7. Normal blood pressure and heart rate;

8. Electrocardiogram (ECG)considered as normal;

9. Results of laboratory tests within the normal ranges.

10. Lung function measurements within the normal ranges.

Exclusion Criteria

1. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before inhalation of the study medication;

2. Pregnant or lactating women or women of childbearing potential, UNLESS they are using one or more of the acceptable methods of contraception. Male subjects not willing to use an acceptable method of contraception.

3. Positive HIV1 or HIV2 serology;

4. Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C;

5. Unsuitable veins for repeated venipuncture;

6. History of substance abuse or drug abuse within 12 months prior to screening visit or with a positive urine drug screen at screening;

7. Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation;

8. Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol;

9. Participation in another clinical trial less than 8 weeks prior to inhalation of the study medication; participation in another clinical trial using radioactive material within 1 calendar year;

10. History of hypersensitivity to M3 Antagonists or any of the excipients contained in any of the formulations used in the trial;

11. Any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, taken in the 14 days (2 months for enzyme-inducing or enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) preceding the first intake of the study drug, with the exception of occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions).

12. Treatment within the previous 3 months with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole).

13. Subjects who refuse to abstain from alcohol or caffeine containing foods or beverages or grapefruit containing foods or beverages from 48 hour prior to the first intake of study medication and for the entire duration of the study.

14. Heavy caffeine drinker.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chiesi Farmaceutici S.p.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Chiesi Farmaceutici SpA

Principal Investigators

Dave Singh, MD

Role: PRINCIPAL_INVESTIGATOR

Medicines Evaluation Unit

Locations

Medicines Evaluation Unit

Manchester, , United Kingdom

Countries

United Kingdom

Related Links

https://www.chiesi.com/clinic/CSR_Synopsis_CCD-0915-PR-0031.pdf

CSR Synopsis available in the Chiesi Clinical Study Register

Other Identifiers

CCD-0915-PR-0031

Identifier Type: -

Identifier Source: org_study_id